-transparent.png){kind=logo}
Glucocorticoids are the mainstay of treatment in patients with polymyalgia rheumatica (PMR). Moreover, lower serum cortisol levels have been reported in patients with PMR, suggesting an important role of impaired hypothalamus-pituitary-adrenal (HPA) axis in the pathogenesis of the disease. Therefore, a good response to glucocorticoids has been recognised as a feature of PMR, even if disagreement remains concerning an exact starting dose, duration of treatment and schedule of administration. The role of glucocorticoids in the pathogenesis of PMR, as well as the available evidence concerning different schedules of glucocorticoid treatment, including administration according to circadian rhythms, are discussed.
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
December 2022,
Journal of the American Association of Nurse Practitioners,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
July 2019,
Biochemical pharmacology,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
August 1990,
British journal of rheumatology,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
January 1982,
Arthritis and rheumatism,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
March 2020,
Irish medical journal,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
October 2023,
The New England journal of medicine,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
May 2016,
Clinical rheumatology,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
December 2006,
Joint bone spine,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
September 2023,
Medicina clinica,
R Caporali, and
M A Cimmino, and
C Montecucco, and
M Cutolo
September 1974,
Deutsche medizinische Wochenschrift (1946),
